Correlation Between Brainstorm Cell and Protalix Biotherapeutics
Can any of the company-specific risk be diversified away by investing in both Brainstorm Cell and Protalix Biotherapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Brainstorm Cell and Protalix Biotherapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Brainstorm Cell Therapeutics and Protalix Biotherapeutics, you can compare the effects of market volatilities on Brainstorm Cell and Protalix Biotherapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Brainstorm Cell with a short position of Protalix Biotherapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Brainstorm Cell and Protalix Biotherapeutics.
Diversification Opportunities for Brainstorm Cell and Protalix Biotherapeutics
-0.63 | Correlation Coefficient |
Excellent diversification
The 3 months correlation between Brainstorm and Protalix is -0.63. Overlapping area represents the amount of risk that can be diversified away by holding Brainstorm Cell Therapeutics and Protalix Biotherapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Protalix Biotherapeutics and Brainstorm Cell is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Brainstorm Cell Therapeutics are associated (or correlated) with Protalix Biotherapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Protalix Biotherapeutics has no effect on the direction of Brainstorm Cell i.e., Brainstorm Cell and Protalix Biotherapeutics go up and down completely randomly.
Pair Corralation between Brainstorm Cell and Protalix Biotherapeutics
Given the investment horizon of 90 days Brainstorm Cell Therapeutics is expected to under-perform the Protalix Biotherapeutics. In addition to that, Brainstorm Cell is 1.41 times more volatile than Protalix Biotherapeutics. It trades about -0.2 of its total potential returns per unit of risk. Protalix Biotherapeutics is currently generating about 0.19 per unit of volatility. If you would invest 107.00 in Protalix Biotherapeutics on September 3, 2024 and sell it today you would earn a total of 65.00 from holding Protalix Biotherapeutics or generate 60.75% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Against |
Strength | Weak |
Accuracy | 100.0% |
Values | Daily Returns |
Brainstorm Cell Therapeutics vs. Protalix Biotherapeutics
Performance |
Timeline |
Brainstorm Cell Ther |
Protalix Biotherapeutics |
Brainstorm Cell and Protalix Biotherapeutics Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Brainstorm Cell and Protalix Biotherapeutics
The main advantage of trading using opposite Brainstorm Cell and Protalix Biotherapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Brainstorm Cell position performs unexpectedly, Protalix Biotherapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Protalix Biotherapeutics will offset losses from the drop in Protalix Biotherapeutics' long position.Brainstorm Cell vs. Protalix Biotherapeutics | Brainstorm Cell vs. Corvus Pharmaceuticals | Brainstorm Cell vs. Aldeyra | Brainstorm Cell vs. Checkpoint Therapeutics |
Protalix Biotherapeutics vs. DiaMedica Therapeutics | Protalix Biotherapeutics vs. Lyra Therapeutics | Protalix Biotherapeutics vs. Centessa Pharmaceuticals PLC |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Other Complementary Tools
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
CEOs Directory Screen CEOs from public companies around the world | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |